Tanya Gupta, MD, medical oncologist in the Stanford University Department of Medicine, Division of Medical Oncology, evaluates fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) and its role in breast ...

In an interview with Targeted Oncology, Hina Saeed, MD, discussed how AI and radiomics are changing the landscape of ...

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...

Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.

Tanya Gupta, MD, discusses the use of ado-trastuzumab emtansine for the treatment of patients with HER2-positive breast cancer.

ADRX-0405 is a novel antibody-drug conjugate targeting STEAP1, and a phase 1a/b study will investigate the agent for the ...

While there have been exciting advancements in the treatment of B-cell acute lymphoblastic leukemia over the course of the past decade, the treatment of older adults remains a challenge.

In separate, live virtual events, Doris Hansen, MD, and Leyla O. Shune, MD, discuss options for a patient with ...

Sarah Sammons, MD, discusses some of the problems seen with brain metastasis in HER2-positive metastatic breast cancer.

The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic ...

The FDA has approved the Ion Torrent Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for ...

Rebecca A. Shatsky, MD, discussed the I-SPY2.2 trial, its novel design, and its implications for the treatment of patients ...